Pharma, Biotech, Medtech, and Digital Health Solicitors

Pharma, Biotech, Medtech, and Digital Health
We work closely with clients in life sciences sectors – pharma, biotech, medtech, and digital health – helping them to achieve their most ambitious goals, both nationally and internationally.

“Shepherd and Wedderburn has a noted practice in the healthcare arena advising clients on an array of matters, including property investment, project development and commercialisation of healthcare technology. The team also has an active presence assisting healthcare groups with operational and regulatory issues affecting care homes. The firm’s clients include care home operators, developers, private contractors and investors.”

Chambers (2025)

The work done in the pharma, biotech, medtech, and digital healthcare sectors is not just life-enhancing but often life-saving. So their importance extends beyond their considerable economic impact.

We are active participants: over time we have developed deep knowledge of these sectors, and built strong relationships of trust with our clients. They include publicly listed companies, SMEs, start-ups and universities, among others; we advise them on a very wide range of critical matters, at every stage from concept through to production at scale. The business landscape is ever-changing, in many ways, including the regulatory regime and technological advances such as the convergence of AI and digital tech. So all businesses in these sectors need to balance risks and opportunities.

Our team includes experts in intellectual property, technology, data, corporate, commercial, employment and immigration law, all with broad experience in the sector. When international advice is required, we call on the resources available in the wider firm, and use our strong relationships in the World Services Group – a global network of 130 firms operating across 145 jurisdictions, of which we were a founder member.

Our depth of practical experience enables us to add another dimension to the advice we provide: anticipating possible future problems and ensuring that the legal arrangements we put in place minimise those risks.

Our expertise includes:

Fundraising and financing
Mergers and acquisitions
Collaborations, joint ventures and strategic partnering arrangements
Research and Development (both academic and industrial)
Clinical trial and study agreements
Protection, acquisition and licensing intellectual property
Manufacturing, supply, distribution and agency agreements
Employment, immigration and employee incentive schemes
Competition and regulation
Advertising and promotion under regulated conditions
Data protection including direct marketing, data usage and security breaches
Exports and sanctions
Inwards investment and international transactions

Meet our key contacts

Joanna Boag-Thomson

Partner

Meet our full team

Joanna Boag-Thomson

Partner

View Profile

Madeleine Gill

Solicitor

View Profile

Cameron Kane

Associate

View Profile

Cath Macrae

Senior Associate

View Profile

Stephen Trombala

Partner

View Profile

Related articles and insights: Pharma, Biotech, Medtech, and Digital Health

Two people working together with an iPad

8 April 2026

The new tax year has begun: are you ready?

Contributor: Gavin Charlton

What businesses who offer employee share incentive schemes should be thinking about as the new tax year begins.

Graphic with a computer and person signing a document

10 December 2025

EMI options – How to get them right

Contributor: Gavin Charlton

Following the expansion of qualifying companies for EMI options in the Autumn Budget we look at the most common mistakes made when implementing an EMI plan and how businesses can avoid them.

3 December 2025

The benefits of EMI share option plans and why more companies should take advantage of them

Contributor: Gavin Charlton

The Autumn Budget expanded the scope of companies who will qualify for Enterprise Management Incentive Plans. To help those considering this type of employee share option plan, we look at the main motivations behind EMI plans and how they can benefit businesses and employees.

26 November 2025

Some budget good news – EMI employee share option plans improved

Contributor: Gavin Charlton

A look into the changes to Enterprise Management Incentives (EMI) employee share option plans is in the Autumn 2025 Budget.

28 October 2025

A world of opportunity

Contributors:
Louisa Knox, Hamish Patrick, Donald Smith, Peter Alderdice

Scotland’s first ever Global Investment Summit saw senior people from business, politics and finance come together to address the nation’s need for investment and growth.

23 September 2021

Bitter pill for the ICO to swallow as fine on pharmacy reduced

Contributor: Ruairidh Leishman

A recent appeal by a pharmacy Doorstep Dispensaree Limited was successful in reducing a Monetary Penalty Notice issued by the Information Commissioner’s Office by approximately two thirds. Ruairidh Leishman, solicitor in our commercial disptues team, explains why.

Contact us